|
Market Closed -
Nasdaq
21:00:00 09/09/2026 BST
|
After hours 01:00:00 | |||
| 135.61 USD | -3.36% |
|
138.14 | +1.87% |
| 09-09 | Moderna Set for 3 Near-Term INT Data Readouts, UBS Says | MT |
| 09-04 | Is the party already over for AI-boosted momentum kings? |  |
| Market Cap | 54.14B 46.59B 43.87B 39.97B 74.78B 5,152B 75.08B 520B 201B 2,625B 203B 199B 8,315B | P/E 2026 * |
-16.1x | P/E 2027 * | -27.5x |
|---|---|---|---|---|---|
| Enterprise Value | 50.49B 43.44B 40.91B 37.27B 69.74B 4,804B 70.02B 485B 187B 2,447B 190B 185B 7,754B | EV / Sales 2026 * |
24x | EV / Sales 2027 * | 21.3x |
| Free-Float |
92.68% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| MRNA | Delayed | |
CBOE
| MRNA | Real-time | |
|
Borsa Italiana
| 1MRNA | End-of-day quote | |
|
London S.E.
| 0A45 | Delayed | |
|
Tradegate
| 0QF | Real-time | |
|
Wiener Boerse
| MRNA | End-of-day quote | |
|
Xetra
| 0QF | Delayed | |
|
Boerse Muenchen
| 0QF | Real-time | |
|
CBOE
| Real-time | ||
|
Mexican S.E.
| MRNA * | End-of-day quote | |
|
Kazakhstan S.E.
| MRNA_KZ | End-of-day quote | |
|
CBOE
| 0A45 | Real-time | |
|
Deutsche Boerse AG
| 0QF | Delayed | |
|
Börse Stuttgart
| 0QF | Delayed | |
|
Lima
| MRNAUS | End-of-day quote | |
|
Swiss Exchange
| MRNA | Delayed | |
|
Swiss Exchange
| MRNA | Delayed |
Last Transcript : Moderna, Inc.
| 1 day | +1.87% | ||
| 1 week | -10.08% | ||
| Current month | -3.37% | ||
| 1 month | +129.19% | ||
| 3 months | +184.12% | ||
| 6 months | +143.29% | ||
| Current year | +359.85% |
| 1 week | 135.52 |  | 154.69 |
| 1 month | 58.6 | | 176.66 |
| Current year | 29.81 | | 176.66 |
| 1 year | 22.28 | | 176.66 |
| 3 years | 22.28 | | 176.66 |
| 5 years | 22.28 | | 458.5 |
| 10 years | 11.54 | | 497.49 |
| Manager | Title | Age | Since |
|---|---|---|---|
Stéphane Bancel
CEO | Chief Executive Officer | 54 | 28/02/2011 |
James Mock
DFI | Director of Finance/CFO | 49 | 05/09/2022 |
Stephen Hoge
PSD | President | 50 | 31/10/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Noubar Afeyan
CHM | Chairman | 63 | 31/01/2012 |
Stéphane Bancel
BRD | Director/Board Member | 54 | 28/02/2011 |
Francois Nader
BRD | Director/Board Member | 69 | 10/12/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 04/09/26 | Exercice | General Counsel | 29,298 | 0.0073% | ||
| 04/09/26 | Exercice | Chief Financial Officer | 29,298 | 0.0073% | ||
| 01/09/26 | Exercice | General Counsel | 15,793 | 0.0040% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.36% | -10.08% | +454.19% | +25.98% | 54.14B | |
| -0.33% | -5.21% | +45.12% | -2.77% | 80.65B | |
| -1.00% | -3.42% | -19.64% | -36.89% | 59.12B | |
| +0.83% | -3.26% | -9.28% | +30.44% | 50.1B | |
| -0.98% | -8.07% | -2.64% | +146.18% | 45.33B | |
| -0.83% | -5.36% | +46.75% | -18.63% | 31.14B | |
| +1.29% | -2.19% | +47.21% | +96.95% | 25.54B | |
| -3.97% | -8.04% | -5.27% | +146.34% | 21.8B | |
| -0.38% | -3.74% | +64.37% | +99.64% | 16.06B | |
| +1.77% | -0.55% | +42.21% | +167.79% | 14.87B | |
| Average | -0.13% | -3.47% | +66.30% | +65.50% | 39.88B | |
| Weighted average by Cap. | -0.09% | -3.73% | +76.97% | +40.97% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.1B 1.81B 1.7B 1.55B 2.9B 200B 2.91B 20.18B 7.8B 102B 7.89B 7.72B 323B | 2.44B 2.1B 1.98B 1.8B 3.37B 232B 3.38B 23.41B 9.05B 118B 9.15B 8.95B 374B |
| Net income | -3.31B -2.85B -2.68B -2.45B -4.58B -315B -4.59B -31.81B -12.29B -161B -12.44B -12.17B -509B | -1.94B -1.67B -1.58B -1.44B -2.69B -185B -2.7B -18.68B -7.22B -94.28B -7.3B -7.14B -299B |
| Net Debt | -3.65B -3.14B -2.96B -2.7B -5.05B -348B -5.07B -35.08B -13.56B -177B -13.72B -13.42B -561B | -2.17B -1.87B -1.76B -1.6B -3B -206B -3.01B -20.83B -8.05B -105B -8.15B -7.97B -333B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/09/26 | US$135.61 | -3.36% | 8,650,474 |
| 08/09/26 | US$140.33 | -3.59% | 10,308,621 |
| 04/09/26 | US$145.55 | -2.23% | 14,966,547 |
| 03/09/26 | US$148.87 | -1.29% | 13,290,379 |
| 02/09/26 | US$150.81 | -2.24% | 16,563,188 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- MRNA Stock
Select your edition
All financial news and data tailored to specific country editions
